(Q40474798)

20 September 2017

1 reference

title

Local therapy for cytomegalovirus retinopathy. (English)

1 reference

20 September 2017

0 references

R E Engstrom

1

1 reference

PubMed ID

7661210

20 September 2017

G N Holland

series ordinal

2

1 reference

PubMed ID

7661210

20 September 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

American Journal of Ophthalmology

20 September 2017

1 reference

20 September 2017

120

1 reference

20 September 2017

3

1 reference

20 September 2017

376-385

1 reference

Treatment of cytomegalovirus retinopathy with ganciclovir

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Long-term intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS. Case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreal ganciclovir in CMV retinitis: case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

High-dose intravitreal gancyclovir for cytomegaloviral (CMV) retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Staphylococcus epidermidis endophthalmitis complicating intravitreal antiviral therapy of cytomegalovirus retinitis. Case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Efficacy of intravitreal foscarnet in a patient with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreal Sustained-Release Ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

BW B759U for cytomegalovirus retinitis: intraocular drug penetration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Retinal Detachments in Patients With Cytomegalovirus Retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Ganciclovir intraocular device and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Ganciclovir intraocular device and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreous granulation tissue and retinal detachment following pars plana injection for cytomegalovirus retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Pathology of cytomegalovirus retinitis treated with sustained release intravitreal ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Xanthomonas maltophilia endophthalmitis after implantation of sustained-release ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Intravitreal toxicity of hydroxyacyclovir (BW-B759U), a new antiviral agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Ocular toxicity of multiple intravitreal DHPG injections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Transscleral iontophoresis of foscarnet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

A histopathologic study of retinal lesions inflicted by transscleral iontophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972168-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(14)72168-3

1 reference

20 September 2017

1 reference

PubMed ID

7661210